Over the last two years, Visikol has developed into a drug discovery contract research organization leader in the fields of digital pathology, 3D tissue imaging, high content screening, 3D cell culture assays and 3D cell culture models. As Visikol continues its growth in 2019, it is excited to announce that it will be bringing on Stewart Hunt as its Director of US Sales.
Stewart has been on the business side of life science research, selling instruments, consumables and laboratory contract services, throughout his career. During his recent five-year tenure with InSphero he was the US General Manger where he developed a US Sales team and established the commercial laboratory operations in Brunswick, Maine. Through these experiences, Stewart has a deep understanding of the 3D cell culture space from both a business, technical and operational stand point. Stewart has a passion for image-based screening services and brings his dynamic business development skills with over 25 years of life science experience to Visikol.
“At Visikol we have always prided ourselves on our deep relationships with clients and ability to design customized drug discovery solutions for a wide range of needs in the in vitro, imaging and image analysis fields. With bringing on Stewart as our Director of US Sales, we will be able to better serve our clients as well as expand our reach so that we can address new client needs,” described Visikol Director of Operations Brian Mulhall.
Stewart will lead Visikol’s commercial efforts in the US and will be the main point of contact for its pharmaceutical Clients. “Expanding our commercial team is a strong focus of ours as we head into 2019 and we look forward to having Stewart lead these efforts as we continue to build out our imaging, advanced cell culture and image analysis services” described Visikol CEO, Dr. Michael Johnson.